Regulatory T cells in the immunotherapy of melanoma

Tumor Biology

Volumn 37, Issue 1, 2016, Pages 77-85

  Ouyang, Zhengxiao ^a   Wu, Hongwei ^a   Li, Linqin ^a   Luo, Yi ^a   Li, Xianan ^a   Huang, Gang ^a  

^a Central South University   (China)

Author keywords

Immunotherapy; Melanoma; Regulatory T cells

Indexed keywords

B RAF KINASE; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2; IPILIMUMAB; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB; TUMOR NECROSIS FACTOR RECEPTOR; CTLA4 PROTEIN, HUMAN; IL2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL FEATURE; DRUG EFFICACY; HUMAN; IMMUNE ESCAPE; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T CELL DEPLETION; T LYMPHOCYTE SUBPOPULATION; TARGET CELL; TREATMENT INDICATION; TUMOR IMMUNITY; ANIMAL; CELL MOTION; CHEMISTRY; DISEASE MODEL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PATHOLOGY; PROCEDURES; SKIN NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL MOVEMENT; CTLA-4 ANTIGEN; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; IMMUNOTHERAPY; INTERLEUKIN-2; MELANOMA; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 84945560658     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4315-0     Document Type: Review

References (94)

1. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol. 2004;150:179–85.
2. Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol. 2012;13:e32–42.
3. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol. 2006;24:175–208.
4. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011;16:5–24.
5. Jandus C, Speiser D, Romero P. Recent advances and hurdles in melanoma immunotherapy. Pigment Cell Melanoma Res. 2009;22:711–23.
6. Fourcade J, Zarour HM. Strategies to reverse melanoma-induced T-cell dysfunction. Clin Dermatol. 2013;31:251–6.
7. Yang S, Fujikado N, Kolodin D, Benoist C, Mathis D. Immune tolerance. Regulatory T cells generated early in life play a distinct role in maintaining self-tolerance. Science. 2015;348:589–94.
8. Peterson RA. Regulatory T-cells: diverse phenotypes integral to immune homeostasis and suppression. Toxicol Pathol. 2012;40:186–204.
9. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10:490–500.
10. Battaglia M, Roncarolo MG. Immune intervention with T regulatory cells: past lessons and future perspectives for type 1 diabetes. Semin Immunol. 2011;23:182–94.
11. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192:303–10.
12. Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol. 2000;164:183–90.
13. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25+ regulatory cells from human peripheral blood express very high levels of CD25 ex vivo. Novartis Found Symp. 2003;252:67–88. discussion 88–91, 106–114.
14. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057–61.
15. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330–6.
16. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003;4:337–42.
17. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 2001;27:18–20.
18. Fontenot JD, Dooley JL, Farr AG, Rudensky AY. Developmental regulation of Foxp3 expression during ontogeny. J Exp Med. 2005;202:901–6.
19. Ndhlovu LC, Takeda I, Sugamura K, Ishii N. Expanding role of T-cell costimulators in regulatory T-cell function: recent advances in accessory molecules expressed on both regulatory and nonregulatory T cells. Crit Rev Immunol. 2004;24:251–66.
20. Antony PA, Restifo NP. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother. 2005;28:120–8.
21. von Herrath MG, Harrison LC. Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol. 2003;3:223–32.
22. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003;3:253–7.
23. Nizar S, Meyer B, Galustian C, Kumar D, Dalgleish A. T regulatory cells, the evolution of targeted immunotherapy. Biochim Biophys Acta. 2010;1806:7–17.
24. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood. 2006;107:2409–14.
25. Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:1169–77.
26. Jandus C, Bioley G, Speiser DE, Romero P. Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood. Cancer Immunol Immunother CII. 2008;57:1795–805.
27. Mougiakakos D, Johansson CC, Trocme E, All-Ericsson C, Economou MA, et al. Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma. Cancer. 2010;116:2224–33.
28. Ladanyi A, Mohos A, Somlai B, Liszkay G, Gilde K, et al. FOXP3+ cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma. Pathol Oncol Res POR. 2010;16:303–9.
29. Mourmouras V, Fimiani M, Rubegni P, Epistolato MC, Malagnino V, et al. Evaluation of tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases. Br J Dermatol. 2007;157:531–9.
30. Vence L, Palucka AK, Fay JW, Ito T, Liu YJ, et al. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2007;104:20884–9.
31. Baumgartner JM, Gonzalez R, Lewis KD, Robinson WA, Richter DA, et al. Increased survival from stage IV melanoma associated with fewer regulatory T Cells. J Surg Res. 2009;154:13–20.
32. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–9.
33. Knol AC, Nguyen JM, Quereux G, Brocard A, Khammari A, et al. Prognostic value of tumor-infiltrating Foxp3+ T-cell subpopulations in metastatic melanoma. Exp Dermatol. 2011;20:430–4.
34. Jiang H, Gebhardt C, Umansky L, Beckhove P, Schulze TJ, et al. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int J Cancer J Int Cancer. 2015;136:2352–60.
35. Gerber AL, Munst A, Schlapbach C, Shafighi M, Kiermeir D, et al. High expression of FOXP3 in primary melanoma is associated with tumour progression. Br J Dermatol. 2014;170:103–9.
36. Mohos A, Sebestyen T, Liszkay G, Plotar V, Horvath S, et al. Immune cell profile of sentinel lymph nodes in patients with malignant melanoma—FOXP3+ cell density in cases with positive sentinel node status is associated with unfavorable clinical outcome. J Transl Med. 2013;11:43.
37. Wei S, Kryczek I, Zou W. Regulatory T-cell compartmentalization and trafficking. Blood. 2006;108:426–31.
38. Kimpfler S, Sevko A, Ring S, Falk C, Osen W, et al. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. J Immunol (Baltimore, Md: 1950). 2009;183:6330–7.
39. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117:1147–54.
40. Alexandrescu DT, Ichim TE, Riordan NH, Marincola FM, Di Nardo A, et al. Immunotherapy for melanoma: current status and perspectives. J Immunother (Hagerstown, Md: 1997). 2010;33:570–90.
41. Baumgartner J, Wilson C, Palmer B, Richter D, Banerjee A, et al. Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells. J Surg Res. 2007;141:72–7.
42. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17:968–75.
43. Eigentler TK, Weide B, de Braud F, Spitaleri G, Romanini A, et al. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17:7732–42.
44. Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20:1600–7.
45. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.
46. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2013;1:32–42.
47. Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, Terwey TH, Kochman AA, et al. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J immunol (Baltimore, Md: 1950). 2006;176:6434–42.
48. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:3167–75.
49. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65.
50. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109–17.
51. Kim-Schulze S, Kim HS, Fan Q, Kim DW, Kaufman HL. Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment. Mol Ther J Am Soc Gene Ther. 2009;17:380–8.
52. Kong LY, Wei J, Sharma AK, Barr J, Abou-Ghazal MK, et al. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother CII. 2009;58:1023–32.
53. Carmenate T, Pacios A, Enamorado M, Moreno E, Garcia-Martinez K, et al. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J Immunol (Baltimore, Md: 1950). 2013;190:6230–8.
54. Keilholz U, Conradt C, Legha SS, Khayat D, Scheibenbogen C, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16:2921–9.
55. Tarhini AA, Kirkwood JM, Gooding WE, Moschos S, Agarwala SS. A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma. Cancer. 2008;113:1632–40.
56. Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC. Regulatory T cells in cancer. Adv Cancer Res. 2010;107:57–117.
57. Powell Jr DJ, Attia P, Ghetie V, Schindler J, Vitetta ES, et al. Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration. J Immunother (Hagerstown, Md: 1997). 2008;31:189–98.
58. Matsushita N, Pilon-Thomas SA, Martin LM, Riker AI. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods. 2008;333:167–79.
59. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 2001;194:823–32.
60. Berd D, Maguire Jr HC, Mastrangelo MJ. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 1986;46:2572–7.
61. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother CII. 2007;56:641–8.
62. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med. 2004;200:771–82.
63. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:5233–9.
64. Klein O, Davis ID, McArthur GA, Chen L, Haydon A, et al. Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX vaccine in patients with advanced melanoma. Cancer Immunol Immunother CII. 2015;64:507–18.
65. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17:2105–16.
66. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol (Baltimore, Md: 1950). 2004;172:6519–23.
67. Foureau DM, Amin A, White RL, Anderson W, Jones CP, et al. Sequential immune monitoring in patients with melanoma and renal cell carcinoma treated with high-dose interleukin-2: immune patterns and correlation with outcome. Cancer Immunol Immunother CII. 2014;63:1329–40.
68. Kwong B, Gai SA, Elkhader J, Wittrup KD, Irvine DJ. Localized immunotherapy via liposome-anchored anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res. 2013;73:1547–58.
69. Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:6747–55.
70. Jacobs JF, Punt CJ, Lesterhuis WJ, Sutmuller RP, Brouwer HM, et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2010;16:5067–78.
71. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother (Hagerstown, Md: 1997). 2005;28:582–92.
72. Tan C, Reddy V, Dannull J, Ding E, Nair SK, et al. Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model. J Transl Med. 2013;11:148.
73. Steitz J, Bruck J, Lenz J, Knop J, Tuting T. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res. 2001;61:8643–6.
74. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006;116:1935–45.
75. Eggermont AM, Robert C. Melanoma in 2011: a new paradigm tumor for drug development. Nat Rev Clin Oncol. 2012;9:74–6.
76. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:1889–94.
77. Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A. 2015;112:6140–5.
78. Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caraco C, et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother CII. 2014;63:675–83.
79. Menard C, Ghiringhelli F, Roux S, Chaput N, Mateus C, et al. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:5242–9.
80. Ribas A, Tumeh PC. The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20:4982–4.
81. Ji HB, Liao G, Faubion WA, Abadia-Molina AC, Cozzo C, et al. Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T cell suppression. J Immunol (Baltimore, Md: 1950). 2004;172:5823–7.
82. Banerjee S, Halder K, Ghosh S, Bose A, Majumdar S. The combination of a novel immunomodulator with a regulatory T cell suppressing antibody (DTA-1) regress advanced stage B16F10 solid tumor by repolarizing tumor associated macrophages. Oncoimmunology. 2015;4:e995559.
83. Robert C, Long GV, Brady B, Dutriaux C, Maio M, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30.
84. Curti BD, Urba WJ. Clinical deployment of antibodies for treatment of melanoma. Mol Immunol. 2015;67:18–27.
85. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.
86. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18:1386–94.
87. Ho PC, Meeth KM, Tsui YC, Srivastava B, Bosenberg MW, et al. Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNgamma. Cancer Res. 2014;74:3205–17.
88. Steinberg SM, Zhang P, Malik BT, Boni A, Shabaneh TB, et al. BRAF inhibition alleviates immune suppression in murine autochthonous melanoma. Cancer Immunol Res. 2014;2:1044–50.
89. Jayaraman P, Alfarano MG, Svider PF, Parikh F, Lu G, et al. iNOS expression in CD4+ T cells limits Treg induction by repressing TGFbeta1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20:6439–51.
90. Forde PF, Sadadcharam M, Hall LJ, Donovan TRO, de Kruijf M, et al. Enhancement of electroporation facilitated immunogene therapy via T-reg depletion. Cancer Gene Ther. 2014;21:349–54.
91. Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, et al. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J immunol (Baltimore, Md: 1950). 2013;190:4899–909.
92. Mattarollo SR, Steegh K, Li M, Duret H, Foong Ngiow S, et al. Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells. Immunol Cell Biol. 2013;91:105–14.
93. Liang SC, Moskalenko M, Van Roey M, Jooss K. Depletion of regulatory T cells by targeting folate receptor 4 enhances the potency of a GM-CSF-secreting tumor cell immunotherapy. Clin immunol. 2013;148:287–98.
94. Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A. 2013;110:17945–50.